The majority of preclinical studies in ALS have relied on transgenic models with overexpression of mutant human superoxide dismutase 1 (SOD1), widely regarded to have failed in terms of translation of therapeutic effects. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.